CD274 and adenocarcinoma: Among patients with adenocarcinoma or squamous cell carcinoma with no actionable mutations and PD-L1 TPS <50%, patients mostly received PBC combination from 2017 to 2018 (85.7% and 78.3%, respectively) and received PD-1/PD-L1 inhibitor combination from 2019 to 2020 (90.8% and 81.0%, respectively, Tables 2A, B).